We are developing a regenerative medicine product for heart failure. The product consists of cardiac cell sheets and biomaterials. We have the technology to efficiently produce cardiomyocytes and vascular endothelial cells from iPS cells. Furthermore, we also have a cell sheet lamination technology using gelatin hydrogel microspheres, which enables us to manufacture multi-layered cardiac cell sheet. We named the product as IHJ-301.
We have almost completed pre-clinical studies of IHJ-301 and we expect that we can get permission to initiate the clinical trial of IHJ-301 within 1 year. Area of Interest
North America
Europe
Southeast Asia
China
Site-visit
Not allowed
SDGs we are working on
3.Good health and well-being5.Gender equality8.Decent work and economic growth16.Peace, justice and strong institutions
Registered Keyword
We are developing a regenerative medicine product for heart failure. The product consists of cardiac cell sheets and biomaterials. We have the technology to efficiently produce cardiomyocytes and vascular endothelial cells from iPS cells. Furthermore, we also have a cell sheet lamination technology using gelatin hydrogel microspheres, which enables us to manufacture multi-layered cardiac cell sheet. We named the product as IHJ-301.
We have almost completed pre-clinical studies of IHJ-301 and we expect that we can get permission to initiate the clinical trial of IHJ-301 within 1 year.
Concept of a regenerative medicine product(IHJ-301) for heart failure